RECEIVED

AUG 0 1 2001 #3

TECH CENTER 1600/2900 APPLICATION NO. ATTY. DOCKET NO. 1735.0440001/RWE/BEC 09/769,420 FORM PTO-1449 APPLICANTS Cai et al. ON DISCLOSURE STATEMENT GROUP FILING DATE January 26, 2001 1614 U.S. PATENT DOCUMENTS EXAMINER NAME CLASS SUB-FILING DATE INITIAL DOCUMENT DATE CLASS NUMBER Schmidt 260 239.3 12/06/1966 10/15/1968 AA1 3,406,168 71 04/14/1981 Bollinger et al. 94 08/09/1978 AB1 4,261,730 514 620 02/27/1997 02/22/2000 Pero et al. AC1 6,028,111 AD1 AE1 AF1 AG1 AH1 AI1 AJ1 AK1 FOREIGN PATENT DOCUMENTS EXAMINER COUNTRY CLASS SUB-TRANSLATION DOCUMENT DATE INITIAL CLASS NUMBER Yes No Yes No Yes No AN Yes No AO Yes No 0 807 633 A2 11/19/1997 Europe AP1 OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Atwell, G.J. et al., "Potential Antitumor Agents. VII. Bisquaternary Salts," J. Med. Chem. 11:300-305, American Chemical Society (1968) Balcells, M. et al., "Synthesis of Phenoxyphenyl Pyridine and Pyrazine Carboxamides. Activity against Cydia pomonella (L.) Eggs, " J. Agric. Food AS 9 Chem. 48:83-87, American Chemical Society (2000). Cooper, G.H. and Rickard, R.L., "Reductive Acylation of 5-Nitropyridines with Anhydrides of Acetic, Phthalic, and Succinic Acids," J. Chem. Soc. C 19:3257-<u>9</u> 3260, Chemical Society (1971)

Initial if reference considered, whether or not citation is in conformance with MPEP 609. EXAMINER: line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

DATE CONSIDERED

EXAMINER

RECEIVED

AUG 0 1 2001

OIP	E							TEC	H CENTER	₽4690\$298 0 3
/						ATTY. DOCKE		APPL	CATION NO	
11	1 2001	F	ORM F	TO-1449		APPLICANTS		<u> </u>	<u>.</u>	
PHENT & TR	INFORM	X101	DIS	CLOSURE STA	ATEMENT	Cai et al.				·
CATA IR	ADEMAR					FILING DATE January 26,		GROUI 1614	,	
					v.s.	PATENT DOCUME				
EXAMINER INITIAL			DOCU	JMENT BER	DATE	NAME		CLASS	SUB- CLASS	FILING DATE
	A	A2								
	A	B2								
	A	C2								
	A	D2					· · · · · · · · · · · · · · · · · · ·		ļ	
	A	E2								
	А	F2								
	A	G2								
	A	Н2								
	A	12								
	A	J2	<u> </u>					ļ <u>-</u>		
	A	К2	<u> </u>			· · · · · · · · · · · · · · · · · · ·			<u> </u>	
					FOREIG	N PATENT DOCUM	MENTS			
EXAMINER INITIAL			DOCU	UMENT BER	DATE	COUNTRY		CLASS	SUB- CLASS	TRANSLATION
42	~ A	L2	1 5	73 576	08/28/1980	Great Britai	n			Yes No
	A	M2	2000	0-256358	09/19/2000	Japan				Yes √No
}	A	N2	WO S	99/24404	05/20/1999	WIPO				Yes No
	A	02	WO (00/06550	02/10/2000	WIPO				Yes √No
	A	P2	WO (00/55114	09/21/2000	WIPO				Yes No
						Title, Date,	Pertinent Page	es, etc.)		
gr	AF	2	10	Photosynth	nesis-Inhibiti	ng Evaluation	ntimycobacteri of Some Anili 45-248, Slovak	des of Su	bstituted	Pyrazine-2-
¥1	1 AS	5	10	Doležal, i Anilides (Veda (1999	of, Substituted	nthesis and P Pyrazine-2-c	hotosynthesis- arboxylic Acid	Inhibitin s," <i>Chem</i> .	g Activity Papers 53	of Some 3:126-130,
T	V AT	r 1	<u>10</u>	Antipsycho	JF. F. et a otics: Synthes Chemical Socie	is and Neuroc	dobenzodiazepi hemical Study,	me Deriva " <i>J. Med</i> .	tives as I	Potential 2107-2114,
EXAMINER	$\frac{1}{2}$		/ /	x /	11 1. 1/1	7,	1	DATE CONS	IDERED G	<u> </u>
EXAMINER line thro	ough ci	ltati	on i	f not in co	onsidered, whet	ther or not considered	itation is in ded. Include co	conformance opy of the	ce with MP	EP 609. Draw th next

RECEIVED

AUG 0 1 2001

TECH CENTER 1600/2900

PEV				_		_		LONOL	175300 TEP
0					ATTY. DOCKET NO. 1735.0440001/RWE	/BEC		CATION NO).
JUL 3 1 2001	E		PTO-1449	, COURT PAIGE	APPLICANTS Cai et al.				
INFO IRADEMA	RMATIO	N DIS	CLOSURE STA	TEMENT	FILING DATE January 26, 2001		GROUP 1614	•	
				v.s.	PATENT DOCUMENTS				
EXAMINER INITIAL		DOC	UMENT BER	DATE	NAME	C	CLASS	SUB- CLASS	FILING DATE
	AA3								
	AB3							ļ	
	AC3	ļ						<u> </u>	
	AD3	-						<u> </u>	
	AE3	+		<u> </u>				<u> </u>	
-	AF3	╁			 				<u> </u>
	AG3	+							
	AI3	+			<u> </u>				
	AJ3								
	акз								
				FOREIG	N PATENT DOCUMENTS			1	
EXAMINER INITIAL		DOC NUM	UMENT BER	DATE	COUNTRY	C	CLASS	SUB- CLASS	TRANSLATION
m	AL3	wo	00/62778	10/26/2000	WIPO		•		Yes No
gr.	АМЗ	WO	01/02354	01/11/2001	WIPO			-	Yes √No
\$	AN3	wo	01/21598	03/29/2001	WIPO				Yes No
-	AO3								Yes
-	AP3								Yes No
	, AES	<u> </u>	OTHER (Incl	uding Author.	Title, Date, Perti	nent Pages	, etc.)		<u></u>
921	AR	11	Studies or (3',5'-bis	the Pyrimidi	"Inhibitors of NF- ne Portion of 2-Chl nyl)-phenyl)carboxim ty (2000)	oro-4-trif	luoromet	thylpyrim	idine-5-[N-
fr	AS	<u>11</u>	Carboxamic Strain and	les: Inhibitio l a Carboxin-R	ed 2-Methylbenzanil on of Complex II Act desistant Mutant Str deademic Press, Inc.	ivity in M ain of <i>Ust</i>	itochono	dria from	a Wild-Type
1									
100	AT /	11	Internation No. PCT/US	onal Search Re 501/02478, mai	port for Internation led May 31, 2001	onal Patent	Applica	ation	
EXAMINER	1/	71		1/1/2	0.	DA	TE CONSI	DERED.	
		<u>//</u>	MG	VOIC	4			1/8/	02
EXAMINER: 1 line through communicatio	citat	ion i	f not in co	nsidered, whe	ther or not citatio not considered. I	n is in con	nformand y of thi	e with MI s form wi	PEP 609. Draw ith next

JUN 2 5 2001 PADEM

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 1735.0440001/RWE/BEC APPLICATION NO. 09/769,420 APPLICANT CAI et al.

INFO	KHAIIO	N DIS	CLOSURE SIF	<u>VI EMBNI</u>	FILING DATE January 26, 2001		GROUP 1614		2900	
				U.S.	PATENT DOCUMENTS					
EXAMINER INITIAL		DOC!	UMENT BER	DATE	NAME	CL	ASS	SUB- CLASS	FILING DATE	
	AA									
	AB	 		_	<u> </u>					
	AC									
	AD	┼		 						
	AE	+		<u> </u>						
	AF AG	+				_				
	AH	+-		<u> </u>						
	AI	+-								
	AJ	1								
	AK									
				FOREIG	N PATENT DOCUMENTS					
EXAMINER INITIAL		DOC!	UMENT BER	DATE	COUNTRY	CL	ASS	SUB- CLASS	TRANSLATION	
94	AL1	WO !	95/25723	09/28/1995	WIPO				Yes No	
J.	AM1	WO	96/20721	07/11/1996	WIPO				Yes No	
J.	AN1	WO	99/36391	07/22/1999	WIPO				Yes No	
gn	A01	WO (00/44216	08/03/2000	WIPO				Yes No	
<u> </u>	AP '								Yes No	
	<u></u>	- 1	OTHER (Inc)	luding Author,	Title, Date, Pertinent F	ages,	etc.)			
FI	AR	<u>1</u>	Vivo Admir	nistration of	ne Therapy of Experimenta Plasmid DNA Coding for Fa iation of Immunologists	as Liga	and,"	J. Immunol		
M	Boirivant, M. et al., "Lamina Propria T Cells in Crohn's Disease and Other Gastrointestinal Inflammation Show Defective CD2 Pathway-Induced Apoptosis," Gastroenterol. 116:557-565, American Gastroenterological Association (March 1999).									
1	Coven, T.R. et al., "PUVA-induced lymphocyte apoptosis: Mechanism of action in psoriasis," Photodermatol. Phytoimmunol. Photomed. 15:22-27, Munksgaard (February 1999).									
EXAMINER	EXAMINER DATE CONSIDERED OOL									
					ther or not citation is i not considered. Include			e with MPE s form wit		

OIPE	\$C.177			Ì				ובטח טב		R L
JUN 2 5 201) <u> </u>				ATTY. DOCKET NO. 1735.0440001/RWE/BEC		APPLI 09/76	CATION N	<u> </u>	
TRADEMA INFO	F.	ORM F	PTO-1449		APPLICANT					罗
TRADE	RMATION	1 DISC	CLOSURE STA	ATEMENT	CAI et al.		T _{CROUP}	<u>7</u>	2001	$\overline{\mathbf{m}}$
			·		FILING DATE January 26, 2001		GROUP 1614		3	
				U.S.	PATENT DOCUMENTS				5	
EXAMINER INITIAL		DOCU NUME	UMENT BER	DATE	NAME	CL	ASS	SUB- CLASS	FILING	DATE
	AA	 		<u> </u>		+		├	 	
	AB	 				+		-	+	
	AC AD	+				+-		 	+	
	AE	 	·			+		 	 	
	AF	1						<u> </u>	T	
	AG		1.							
	АН	lacksquare							 	
	AI .	↓				_		 	 	
	AJ	 						 	+	
	AK	<u> </u>		FOREIC	T DEMENTS DOCUMENTS			<u> </u>		
EXAMINER		T		FOREIG	N PATENT DOCUMENTS	\top			\top	
INITIAL		DOCU	UMENT BER	DATE	COUNTRY	CLi	ASS	SUB- CLASS	TRANSL	
	AL	<u> </u>								Yes No
	AM									Yes No
	AN									Yes No
	AO					1				Yes No
	AP	<u> </u>				1				Yes No
	. At	Т,	OTHER (Inc.	luding Author,	Title, Date, Pertinent Pag	res,	etc.)	<u></u>	<u> </u>	
In	AR	<u>2</u>	Ellis, R.I	E. <i>et al.,</i> "Med	chanisms and Functions of (Reviews, Inc. (1991).			" Annu. I	Rev. Cel	1.
Tu	AS	<u>2</u>	in drug-in		volvement of the CD95 (APO- is in leukemia cells," <i>Natu</i>					tem
Th	AT	<u>2</u>	Poly(ethy)	lene glycol) Pr 667, American ("Drug Delivery Systems Emprodrugs of Amine-Containing Chemical Society (September	g Com r 199	npounds 99). (F	s," <i>J. Med</i> Published	d. Chem.	
EXAMINER	1/ /	1/	MS.	DIAI	Th.	DATE	CONSI	DEREP 8	a	_
EXAMINER: VI	citati	ion if	f not in co	insidered, whet informance and	ther or not citation is in not considered. Include c	conf	ormand of the	e with MP s form wi	EP 609. th next	Draw

JUN 2 5 2007 JUN 2

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

		品	Page	3	8
ATTY. DOCKET NO. 1735.0440001/RWE/BEC	APPLICATION 09/769,420	ME	_ 0		1
APPLICANT CAI et al.		3 160	2. 20	 	
FILING DATE	GROUP	3	01	TT	П

					January 26, 2001	1614				
				v.s.	PATENT DOCUMENTS		8			
EXAMINER INITIAL		DOCU	JMENT BER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE		
	AA									
	AB									
	AC									
	AD	<u> </u>								
	AE	ļ								
	AF	<u> </u>								
	AG	ļ								
	AH	ļ					ļ			
	AI	<u> </u>								
-	AJ									
	AK	J	·		<u> </u>					
	1	1		FOREIC	O PATENT DOCUMENTS	1	•	<u> </u>		
EXAMINER INITIAL		DOCT NUME	JMENT BER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION		
	AL							Yes No		
	AM							Yes No		
	AN							Yes No		
	AO							Yes No		
	AP							Yes No		
		(OTHER (Incl	uding Author,	Title, Date, Pertinent Page	ges, etc.)				
44	AR	<u>3</u>	Heenen, M. keratinocy	. et al., "Me ytes," Arch.	thotrexate induces apoptoti Dermatol. Res. 290:240-245,	c cell deam	ch in huma /erlag (19 ,	n 98).		
n	Infante, A.J. et al., "The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis," J. Pediatr. 133:629-633, Mosby (1998).									
Ta	Leu, YL. et al., "Design and Synthesis of Water-Soluble Glucuronide Derivatives of Camptothecin for Cancer Prodrug Monotherapy and Antibody-Directed Enzyme Prodrug Therapy (ADEPT)," J. Med. Chem. 42:3623-3628, American Chemical Society (September 1999). (Published on Web, August 24, 1999).									
EXAMINER	Ma	nu	165(MIN	12	DATE CONSI	DER PO			
	citati	on if	f not in co		ether or not citation is in not considered. Include of					

JUN 2 5 2001 W

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

			Page 4	0f J8
ATTY. DOCKET NO.	APPLICATION	N O.	0	П
1735.0440001/RWE/BEC	09/769,420	<u> </u>	2	
APPLICANT		160	20	~
CAI et al.			;	Ш
FILING DATE	GROUP)67	<u> </u>	

					1000001			
	· T			U.S.	PATENT DOCUMENTS	<u> </u>	· ·	
EXAMINER INITIAL			UMENT	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA							
	АВ							
	AC							
	AD							
	AE	Ι						
	AF							
	AG							
	AH	ــــــــ						
	AI	↓						
	AJ	<u> </u>			·			
	AK	<u> </u>						
				FOREIG	N PATENT DOCUMENTS			
EXAMINER INITIAL		DOC	UMENT BER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL							Yes No
	AM							Yes No
	AN							Yes No
	AO							Yes No
	AP			-				Yes No
	712	<u> —</u>	OTHER (Incl	uding Author	Title, Date, Pertinent Pa	uges etc.)		1.00
	П		T THER (INCI	dding Author,	Title, Date, Pertinent Pa	iges, etc.)		
The	AR	<u>4</u>	its role i		"Regulation of B cell apo oment of autoimmune disease dos (1998).			
gry	AS	<u>4</u>	Consequenc	ce of Deficien	Resistance of CD95- and Data Activation of Caspases can Society of Hematology	(ICE/Ced-3	Apoptosis Proteases)	as a ," <i>Blood</i>
T	AT	<u>4</u>			Strasser, "Apoptosis and au ag (January 1999).	utoimmune d	isease," I	nflamm. Res.
EXAMINER) h	M	MGS	1/1/1		DATE GONS	DEREDO	•
EXAMINER: I line through communication	citati	on i	eference co f not in co	nsidered, whe	ther or not citation is in not considered. Include	conformanc	ce with MPI s form wit	EP 609. Draw th next

(O 1 P E	37 35
	PADEMARKS	


FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

		<u> </u>	ag a= 5	dt 8
ATTY. DOCKET NO.	APPLICATION	NO.	7=	\Box
1735.0440001/RWE/BEC	09/769,420		Ó	
APPLICANT		تت	100	
CAI et al.		<u> 6</u>	20	$ \leftarrow $
FILING DATE	GROUP	00/2	01	m

					FILING DATE January 26, 2001	GROUP	7,7				
	-			U.S.	PATENT DOCUMENTS		=====	3			
EXAMINER INITIAL		DOCU	UMENT BER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE			
	AA										
	AB						_				
_	AC										
	AD										
	AE										
	AF										
	AG										
	АН	10									
	AI										
	AJ					_					
	AK										
	•			FOREIG	N PATENT DOCUMENTS						
EXAMINER INITIAL		DOCU	UMENT BER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION			
	AL							Yes No			
	AM							Yes No			
	AN							Yes No			
-	AO							Yes No			
	AP	1						Yes No			
	1 * 5*		OTHER (Incl	uding Author.	Title, Date, Pertinent Pa	ages, etc.)					
tu	AR	<u>5</u>	Ohsako, S.	. and K.B. Elk	on," Apoptosis in the efferosis and thyroiditis," Co	ector phase	of autoim	mune 3-21,			
fr	AS	<u>5</u>		renius, S., "Apoptosis: molecular mechanisms and implications for human sease," <i>J. Internal Med. 237</i> :529-536, Blackwell Science Ltd. (1995).							
~~	АТ	<u>5</u>	Ozawa, M. et al., "312-nanometer Ultraviolet B Light (Narrow-Band UVB) Induces Apoptosis of T Cells within Psoriatic Lesions," J. Exp. Med. 189:711-718, The Rockefeller University Press (February 1999).								
EXAMINER	1 0	. ,	7///			DATE CONSI	PERED /	~			

EXAMINER! Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 1735.0440001/RWE/BEC 09/769,420 TAPPLICANT CAI et al.

FILING DATE GROUP January 26, 2001 1614

				Danaary 207 200					
			ט	.S. PATENT DOCUMENTS					
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE		
	AA								
	AB				,				
	AC								
	AD								
	AE								
	AF						<u>`</u>		
	AG								
	АН								
	AI								
	AJ								
	AK								
	1000		FOR	EIGN PATENT DOCUMENT	<u>s</u>	-			
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION		
	AL						Yes No		
	AM						Yes No		
	AN						Yes No		
	AO						Yes No		
	AP						Yes No		
	1	OTHER (Ir	cluding Auth	or, Title, Date, Per	tinent Pages, etc.)				
gu	AR	Savill,	J., "Apoptos	sis in resolution of akocyte Biology (1997	inflammation," J.	÷	Biol. 61:375-		
772	Schmitt, E. et al., "The Bcl-xL and Bax-α control points: modulation of apoptosis induced by cancer chemotherapy and relation to TPCK-sensitive protease and caspase activation," Biochem. Cell Biol. 75:301-314, NRC Canada (1997).								
gr	АТ	6 Thornber 53:478-4	rry, N.A., "T	The caspase family of ish Council (1997).	cysteine protease:	s," Br. Me	d. Bull.		
EXAMINER) h	Mull	Mp 1-	Le	DATE CONS	FIDE FIDE	02		
EXAMINER: I	citat:	ion if not in	considered, conformance	whether or not citate and not considered.	ion is in conformar Include copy of th	de with Mi	PEP 609. Draw		

JUN 2 5 2001	77 30
TA TRADEMARKO	FO

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

		ोर्म	age 🗆	οţ	- 8
ATTY. DOCKET NO. 1735.0440001/RWE/BEC	APPLICATION 09/769,420	NOE	- 0	1	\overline{D}
APPLICANT			-,-	-	\equiv
CAI et al.		_60	_20	<	
FILING DATE	GROUP	2/0	01	T	Π

Draw

					January 26, 2001	1614				
U.S. PATENT DOCUMENTS										
EXAMINER INITIAL		DOCU	UMENT BER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE		
	AA				333 334 334					
	AB	[
	AC									
	AD	<u> </u>								
	AE	<u> </u>								
	AF									
	AG	<u> </u>								
	АН									
	AI	<u> </u>								
	AJ	<u> </u>						<u> </u>		
	AK									
				FOREIG	N PATENT DOCUMENTS			1		
EXAMINER INITIAL		DOCU	UMENT BER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION		
			. –					Yes No		
	AL	<u> </u>						Yes		
	AM	<u> </u>		***			_	No		
	AN							Yes No		
			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	*				Yes		
<u></u>	AO	<u> </u>					 	No Yes		
	AP	<u> </u>						No		
	OTHER (Including Author, Title, Date, Pertinent Pages, etc.)									
Tu	[AR	Thornberry, N.A., "Caspases: key mediators of apoptosis," <i>Chemistry & Biology</i> 5:R97-R103, Current Biology Ltd. (1998).								
44	AS	<u>7</u>	with CD95	Vaishnaw, A.K. et al., "The molecular basis from apoptotic defects in patients with CD95 (Fas/Apo-1) mutations," <i>J. Clin. Invest.</i> 103:355-363, American Society for Clinical Investigation (February 1999).						
gr	Wakisaka, S. et al., "Modulation by proinflammatory cytokines of Fas/Fas ligand-mediated apoptotic cell death of synovial cells in patients with rheumatoid arthritis (RA)," Clin. Exp. Immunol. 114:119-128, Blackwell Science (1998).							ımatoid		
			11/1	1 11 11		I DAMES COME	TARDED S			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. line through citation if not in conformance and not considered. Include copy of this form with next

communication to Applicant.

JUN 2 5 2001 W	
FORM PTO-144	9
THEODMATION DISCLOSUDE	י פידי

ATEMENT

		Cray	e zar o) Tr
ATTY. DOCKET NO.	APPLICATION N	::][
1735.0440001/RWE/BEC	09/769,420	=	0	_Ò
APPLICANT		'	2	
CAI et al.			2	<
FILING DATE	GROUP	8	00	

				FILING DATE January 26, 2001	GROUP 1614			00/2 50		
				U.S.	P.	ATENT DOCUMENTS				8 0
EXAMINER INITIAL		DOC!	UMENT BER	DATE	1	VAME	CL	ASS	SUB- CLASS	FILING DATE
	AA									
	AB									
	AC				Ŀ					
	AD									
	AE				\perp					
	AF				\perp	,,				
	AG				\perp					
	AH									
	AI				\perp					
	AJ						<u> </u>		ļ	`
	AK			<u> </u>						
				FOREIG	GN	PATENT DOCUMENTS	,			
EXAMINER INITIAL		DOC!	UMENT BER	DATE	(COUNTRY	CL	ASS	SUB- CLASS	TRANSLATION
	AL									Yes No
	AM									Yes No
	AN							-		Yes No
	AO					_				Yes No
-	AP				T					Yes No
			OTHER (Inc.	Luding Author,	, I	itle, Date, Pertinent Page	∍s,	etc.)		
Ty	Wyllie, A.H., "Cell death: a new classification separating apoptosis from necrosis," in <i>Cell death in biology and pathology</i> , Bowen, I.D. and R.A. Lockshin, eds., Chapman and Hall, 1981, pp. 9-34.						from A. Lockshin,			
94	AS	8	Wyllie, A.H. et al., "Cell Death: The Significance of Apoptosis," Intl. Rev. Cytol. 68:251-306, Academic Press, Inc. (1980).							
g	Zhou, T. et al., "Bisindolymaleimide VIII facilitates Fas-mediated apoptosis and inhibits T cell-mediated autoimmune diseases," Nature Med. 5:42-48, Nature Publishing Group (January 1999).							optosis and ature		
EXAMINER) /	120	/).	///////////////////////////////////////	//	′	DATE	CONSI	PERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.